文献速递产科生殖医学

澳大利亚生育治疗与脑性瘫痪风险关联的变迁

Fertility treatment and risk of cerebral palsy: has the association changed in Australia?
PubMed 文献 · Hum Reprod · 2026-01-01

结果显示未治疗不孕女性子代脑性瘫痪风险未增加,ART子代风险下降,OI单药治疗子代风险最高。

要点

  • 未治疗不孕女性子代脑性瘫痪风险未增加。
  • ART子代脑性瘫痪风险随时间下降。
  • OI单药治疗子代脑性瘫痪风险最高。

核心结论

  • 未治疗不孕女性子代脑性瘫痪风险未增加,ART子代风险下降,OI单药治疗子代风险最高。

主要发现

  • 脑性瘫痪诊断率:ART子代29例(2.9/1000活产,95%CI 1.92-4.11),OI子代16例(3.9/1000活产,95%CI 2.23-6.33),未治疗不孕子代23例(2.0/1000活产,95%CI 1.26-2.99),自然受孕子代610例(2.0/1000活产,95%CI 1.84-2.16)。
  • 分层分析显示,风险仅增加于早产(<37周)的ART双胎(aRR 2.8,95%CI 1.42-5.39)和早产的OI单胎(aRR 2.9,95%CI 1.41-5.84)。
  • 单胚胎移植(SET)后双胎比例随时间增加,SET后双胎中90.7%为同性别,估计81%为单卵双胎,多数在单囊胚移植后受孕。
  • 囊胚SET后单卵双胎率高于卵裂期SET(患病率比1.7,95%CI 1.07-2.73)。

临床怎么用

  • 避免多胚胎移植仍然重要。
  • 应探索减少单卵双胎的胚胎培养、操作和冷冻策略。
  • OI受孕子代脑性瘫痪风险最高,可能需要更密切监测。
  • 治疗前咨询应继续推广SET并告知胚胎分裂的小风险,与计划使用OI者讨论多胎风险。

局限性

  • 不孕组脑性瘫痪儿童数量少,无法对妊娠并发症和ART周期特征进行更详细分析。
  • 需要更大规模人群的更近期数据来确认囊胚移植、SET后双胎及OI单药治疗后脑性瘫痪风险是否增加。
  • 缺乏合子性数据,使用Weinberg差异规则估计单卵双胎率可能导致部分错误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the association between treated (ART, ovulation induction (OI)) and untreated subfertility and risk of cerebral palsy (CP)? SUMMARY ANSWER: There is no increased risk of CP in births to subfertile untreated women; the risk of CP has declined in ART conceptions (IVF, ICSI) and is greatest in births conceived using OI medications as a sole therapy. WHAT IS KNOWN ALREADY: Nordic data suggest a decline in risk of CP for ART births over time with the shift to single embryo transfer (SET), but there are no recent data from other countries and no Australian data for births after 2002. Few studies have examined the risk of CP in births conceived after OI or untreated subfertility; these comparison groups may assist in separating ART treatment effects from potential effects of subfertility itself. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study using linked population-based data for women with a live birth (LB) in Western Australia from 2003 to 2014, corresponding to 10 126 ART births (3.1%), 4102 births after OI (1.2%), 11 554 births to subfertile untreated women (3.5%), and 305 508 (92.2%) births to fertile women conceiving naturally. PARTICIPANTS/MATERIALS, SETTING, METHODS: Statutory ART, birth, hospital, CP, and pharmacy data were linked to identify four 'conception groups' (ART, OI, subfertile untreated, and fertile natural conceptions), outcome data, and potential confounders. CP descriptions were verified at 5 years of age. Birth prevalence of CP was calculated for each conception group per 1000 LB. Poisson regression with robust standard errors was used to estimate adjusted risk ratios (aRR) for CP with adjustment for maternal demographic characteristics, pre-existing conditions, and adverse obstetric history (with 95% CI). Births to fertile women were the reference group. Analyses included all children and singletons and twins separately. Weinberg's differential rule was used to estimate the rate of monozygotic twinning across our four conception groups and, for ART births, by length of embryo culture. MAIN RESULTS AND THE ROLE OF CHANCE: CP was diagnosed in 29 ART children (2.9/1000 LB; 95% CI 1.92-4.11), 16 children born after OI (3.9/1000 LB; 95% CI 2.23-6.33), 23 children in the subfertile untreated group (2.0/1000 LB; 95% CI 1.26-2.99), and 610 in the fertile group (2.0/1000 LB; 95% CI 1.84-2.16). When stratified by plurality and prematurity, risk was increased only for ART twins (aRR 2.8, 95% CI 1.42-5.39) born preterm (<37 weeks) and OI singletons (aRR 2.9, 95% CI 1.41-5.84) born preterm. Twins after SET comprised an increasing proportion of all ART twins over time, and of all ART twins with CP. Most twins after SET were same-sex twins (90.7%) and we estimated that 81% were monozygous, with the majority conceived after the transfer of a single blastocyst. The monozygotic twinning rate was higher after blastocyst-SET compared with cleavage-SET (prevalence ratio 1.7 (95% CI 1.07-2.73)). LIMITATIONS, REASONS FOR CAUTION: Small numbers of children with CP in subfertile groups prevented more detailed analyses of pregnancy complications and ART cycle characteristics. More recent data from larger populations are required to confirm whether risk of CP is increased following blastocyst transfer, in twins after SET, and following OI as a sole therapy. As zygosity data were not available, Weinberg's differential rule was used to estimate the rate of monozygotic twinning and may have led to some misclassification. WIDER IMPLICATIONS OF THE FINDINGS: Prevalence of CP following ART has declined in Western Australia, as in the Nordic countries. Avoiding multiple embryo transfer remains important. Monozygotic twinning after SET may increase the risk of CP for ART twins and is more common after blastocyst compared with cleavage-stage transfer. Embryo culture, manipulation, and freezing strategies to reduce monozygotic twinning should be explored. Data about OI (as a sole therapy) are not routinely collected in most countries, but OI-conceived births had the highest risk of CP and may warrant closer scrutiny. Pre-treatment counselling should continue to promote SET while incorporating the small risk of embryo splitting; risk of multiple birth should be discussed with those planning to use OI. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Australian National Health and Medical Research Council, grant number 1086530 (to M.H.) and The Research Foundation of Cerebral Palsy Alliance, grant number 06221 (to M.H.). The sponsors had no role in the design or conduct of the study, or the decision to submit for publication.Professor Hart is the Medical Director of Fertility Specialists of Western Australia and National Medical Director of City Fertility Clinic, a shareholder in CHA SMG; he has received accommodation support from Merck to attend ESHRE and has received travel and accommodation support, as well as educational sponsorship from MSD, Merck-Serono, Origio, Igenomix, and Ferring Pharmaceuticals. He has also received personal fees for presenting a Merck webinar. There are no other conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Hansen M, Kemp-Casey A, McIntyre S, et al. Fertility treatment and risk of cerebral palsy: has the association changed in Australia? Hum Reprod. 2026. PMID: 42177772. doi:10.1093/humrep/deag076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。